Mon 10 Nov
8:30 - 9:45
Plenary Session: Welcome Remarks—Celebrating 30 Years of ISPOR
Join us as we kick off ISPOR Europe 2025. This year, as ISPOR celebrates its 30th Anniversary, the conference theme is, "Powering Value and Access through Patient-Centered Collaboration." Hear from ISPOR leadership and key stakeholders as they reflect on 3 decades of advancing health economics and outcomes research (HEOR) excellence and explore the power of global collaboration in shaping the future of healthcare decision making.
Immediately following the opening presentation, the Keynote Speaker, Dave Snowden will take the stage.
Speaker
-
Rob Abbott
ISPOR, Lawrenceville, NJ, United States
Plenary Session: Keynote Address—Decision Making in a Complex World
We are excited to welcome Dave Snowden, internationally recognized thinker, researcher, and founder of the Cynefin® -Framework©, as a keynote speaker at ISPOR Europe 2025. Dave brings fresh perspectives from the field of complexity science—exploring how organizations can make better decisions in uncertain, dynamic environments. His keynote will connect this innovative thinking to healthcare and patient journeys, offering our audience a thought-provoking look at how complexity-based approaches can advance patient-centric decision making and reshape the future of health economics and outcomes research (HEOR).
Immediately following the Keynote Address, the scientific plenary panel will take the stage.
Speaker
-
Dave Snowden, PhD
The Cynefin Company, Brecon, Powys, Wales, United Kingdom
Dave Snowden is the Founder and Chief Scientific Officer of The Cynefin Co. and Director of the Cynefin Centre for Applied Complexity. His international work spans government and industry, examining complex strategic, organisational, and decision-making issues. He has pioneered a science-based approach, drawing on anthropology, the cognitive sciences, and complex adaptive systems theory. This approach, known as naturalising sense-making, has been acknowledged as one of five distinct schools of sensemaking/sense-making.
He is the principal author of a joint publication between the Cynefin Centre and the Future Systems Directorate of the European Union: ' Managing complexity (and chaos) in times of crisis—a field guide for decision-makers. A review by Durham University identified him as one of the leaders in applying complexity science to organisations.
He is a visiting Professor at the University of Hull and has previously held similar posts at the University of Bangor, Hong Kong PolyU, Warwick, Pretoria and Stellenbosch. He held the position of senior fellow at the Institute of Defence and Strategic Studies at Nanyang Technological University and the Civil Service College in Singapore during a sabbatical period at Nanyang Technological University.
He has created many methods and frameworks, including the Cynefin Framework. His paper with Boone on Cynefin and Leadership was the cover article for the Harvard Business Review in November 2007. He also won the Academy of Management award for the best practitioner paper in the same year. He had previously won a special award from the Academy for his original work in knowledge management. He is an editorial board member of several academic and practitioner journals in knowledge management. He was the Editor-in-Chief of E:CO, one of the first journals to cover applied complexity science. In 2006, he served as Director of the EPSRC (UK) research programme on emergence, and in 2007, he was appointed to an NSF (US) review panel on complexity science research. In 2023, he received an award from Hull University for his "Outstanding Contribution to Systems Thinking".
He is the principal designer of SenseMaker®, the world's first distributed ethnography software, and led the application of this technology to create a radically new approach to capturing data from patients, work that was acknowledged in a report by the CMO as one of the few examples of authentic patient engagement. The work is now developing into integrated health care, measuring the placebo effect, and creating new approaches to distributed decision-making to reduce bureaucracy and increase clinical engagement - work that has broader implications outside the health sector.
Plenary Session: Patient Engagement in Healthcare Investments—A Promise or a Practice?
Patient engagement is a key topic in many industry settings and interactions, but has it led to tangible results? How can we enhance the impact of patient engagement? In this panel, key stakeholders, including payers, investors, industry, regulators, and patients, will have an open discussion about how patient engagement can be improved to lead to tangible results. A key aim of this discussion is to set actionable deliverables for the next 5 years to improve access, relevance and efficiency based on patient input and involvement.
Moderator
-
Joep Muijrers
Gilde Healthcare Partners, Utrecht, Netherlands
Joep joined Gilde Healthcare in 2021. He focuses on investing in late-stage opportunities including publicly traded companies that deliver better care at lower cost. He is actively engaged in multi-stakeholder interaction and is responsible for coordinating Gilde’s Impact Council.
Before joining Gilde, he served as CFO and Chief of Portfolio Strategy at Boston-based biotech company PureTech Health (PRTC), developing highly differentiated medicines for devastating diseases. Prior to PureTech, Joep worked as Partner and Portfolio Manager at LSP for 12 years and gained experience in life sciences investment banking in his role as Director of Corporate Finance and Capital Markets at Fortis Bank.
Joep holds a PhD in Molecular Biology from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and a Master’s degree in Biochemistry from the University of Nijmegen, the Netherlands.
Speakers
-
Carole Longson, PhD
University of Manchester, Manchester, United Kingdom
Carole Longson has over 30 years of executive and board experience in life sciences and is an internationally respected leader in Health Technology Assessment and Market Access. After a career in drug discovery at GSK, she spent 18 years at NICE pioneering its Technology Appraisal and Health Tech Evaluation programs, later serving as Chief Scientific Officer at the Association of the British Pharmaceutical Industry. A former HTAi President and EUnetHTA Executive Committee member, she has advised the European Commission and WHO. She is currently Vice Chair of Medicines Discovery Catapult UK and senior counsel in HTA and market access.
-
Steffen Thirstrup, PhD, MD
European Medicines Agency (EMA), Amsterdam, Netherlands
Steffen Thirstrup is a medical doctor and board-certified specialist in clinical pharmacology and therapeutics. He holds a PhD in pharmacology and has a long background in clinical internal medicine with special emphasis on adult respiratory medicine. Additionally, Dr. Thirstrup was appointed adjunct professor in pharmacotherapy at the Faculty of Health Sciences, University of Copenhagen, in 2012.From 2004-09 Steffen Thirstrup worked at Danish Medicines Agency first as the Danish member of CHMP at the European Medicines Agency (EMA) for five years including 10 months as joint CHMP- and CAT-member, followed by a short period as head of Danish Institute for Rational Pharmacotherapy dealing with HTA and best practice guidelines for primary care. In 2011 Prof. Thirstrup rejoined the licensing division at the Danish Medicines Agency acting as Head of Division for Medicines Assessment and Clinical Trials. During this period Prof Thirstrup co-chaired the European Commission’s working group on market access for biosimilars medicinal products and acted as key scientific contact for the managing entity of the IMI beneficiaries for the PROTECT collaboration (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium).
In March 2013, Prof Thirstrup joined the pharmaceutical consultancy company NDA Group AB as a full-time medical advisor on NDA’s regulatory advisory board. In April 2014 Prof Thirstrup was appointed as director for the Regulatory Advisory Board at NDA Regulatory Services Ltd.
Since June 2022 Prof Thirstrup has been the Chief Medical Officer at the European Medicines Agency, Amsterdam, The Netherlands
-
David H.-U. Haerry
Positivrat, Zürich, Switzerland
David Haerry has been writing about scientific research and from medical conferences in lay language since 1996.
He has been involved in projects to educate healthcare professionals and doctors for over 30 years and became Secretary General of the Swiss Academic Foundation on Education in Infectious Diseases SAFE-ID in 2015. He has been involved with the European Medicines Agency EMA and Swissmedic for many years, and he played a key role in the EUPATI IMI project. He is a member of the Executive Committee of PFMD and a consultant on patient-centred clinical research and medicine throughout Europe.
He is co-author of numerous publications in the fields of infectious diseases, doctor-patient communication, research ethics and pharmacovigilance.
-
Luc Truyen, MD, PhD
Argenx, Boston, MA, United States
Luc Truyen is the Chief Medical Officer of argenx and joined the company in 2021. Previously, Luc was with the Johnson & Johnson organization for over 20 years holding various leadership positions, primarily within neuroscience. He has a strong track record in clinical development resulting in several global innovative drug approvals.
In his most recent position, Luc was global head of development for neuroscience at JNJ and managed the strategy and delivery of the early and late portfolio of assets for mood disorders and schizophrenia, and neurodegenerative and neuroinflammatory disorders.
His broad-based experience also includes leading global clinical development operations for the whole JNJ pharmaceutical group as well as serving as Head of R&D and CMO of Janssen Alzheimer Immunotherapy (JAI), an internal spin-out from JNJ. Luc holds an M.D. and Ph.D. in Neurology from the University of Antwerp.
Tue 11 Nov
Plenary Session: Welcome Remarks, Presidential Address, and Awards
Start Day 2 of ISPOR Europe 2025 with inspiring insights from the Society’s leadership. This session will feature welcome remarks, followed by addresses from the ISPOR President and WHO Europe, and an acknowledgement of prestigious ISPOR awards.
Immediately following the opening presentations, the scientific plenary panel will take the stage.
Speakers
-
Uwe Siebert, MPH, MSc, ScD, MD
UMIT TIROL - University for Health Sciences and Technology; Harvard Chan School of Public Health, Hall in Tirol, Austria
Uwe Siebert, MD, MPH, MSc, ScD, is a professor of Public Health, Medical Decision Making and Health Technology Assessment (HTA), chair of the Department of Public Health, Health Services Research and HTA at UMIT TIROL-University for Health Sciences and Technology in Austria and director of the Division for HTA in the ONCOTYROL–Center for Personalized Cancer Medicine in Austria. He is also adjunct professor of Epidemiology and Health Policy & Management at the Harvard T.H. Chan School of Public Health and Affiliated Researcher in the Program on Cardiovascular Research at the Institute for Technology Assessment and Department of Radiology at the Massachusetts General Hospital, Harvard Medical School, Boston.
After medical school, he worked for several years as a physician in international public health projects in West Africa, Brazil, and Germany. He then earned an MPH at the Munich School of Public Health and completed an MSc in Epidemiology and a ScD in Health Policy and Management with a concentration in decision sciences at the Harvard School of Public Health.
His research interests include applying real-world evidence-based quantitative, causal and translational methods from public health, epidemiology, artificial intelligence, comparative effectiveness research, health services and outcomes research, economic evaluation, modeling, and health data a d decision science in the framework of health care policy advice and HTA as well as in the clinical context of routine health care, clinical guideline development, public health policies and patient guidance. His research focuses on cancer, infectious disease, cardiovascular disease, neurological disorders, and others.
He has been leading projects/work packages in several EU FP7, H2020 and Horizon Europe projects (eg, ELSA-GEN, BiomarCaRE, MedTecHTA, DEXHELPP, EUthyroid, FORECEE, MDS-RIGHT, RECETAS, CORE-MD, EUREGIO-EFH, CIDS, OnCoVID, 4D PICTURE, CATALYSE). He teaches HTA, health economics, modeling, epidemiology, causal inference and target trial emulation, and data and decision science for academia, industry, and health authorities in Europe, North and South America, and Asia. He directs the Continuing Education Program on Health Technology Assessment & Decision Sciences (htads.org).
He has served as member of the ISPOR Directors Board and as president of the Society for Medical Decision Making (SMDM). He is a leadership member of the ISPOR Personalized/Precision Medicine SIG, a member of the Latin America Consortium Advisory Committee of ISPOR, and co-chair of the ISPOR-SMDM Modeling Good Research Practices Task Force. He is a member of the Oncology Advisory Council and the National Committee for Cancer Screening of the Austrian Federal Ministry of Health.
He has authored more than 400 publications (> 30,000 citations, H index > 80), and is editor of the European Journal of Epidemiology. Further information Internet: http://htads.org, umit-tirol.at/dph, hsph.harvard.edu/uwe-siebert, Twitter: @UweSiebert9, LinkedIn: uwe-siebert9.
-
Natasha Azzopardi-Muscat, MD, PhD
WHO Europe, Copenhagen, Denmark
Dr Natasha Azzopardi-Muscat, Director of the Division of Health Systems, WHO Regional Office for Europe.
Dr Natasha Azzopardi-Muscat is a medical doctor and a specialist in public health medicine.
Following her qualification as a medical doctor from the University of Malta in 1995, Dr Azzopardi-Muscat worked in various clinical specialties, including maternal and child health, mental health, and primary care. Having successfully completed a Master’s Degree in Health Services Management at the London School of Hygiene and Tropical Medicine and the London School of Economics and Political Science she returned to work at the Ministry of Health in Malta.
Between 2001 and 2013, she occupied various senior positions in the Ministry including Director for EU and International Affairs, Director General for Strategy and Chief Medical Officer.
In 2016 she obtained her PhD from the University of Maastricht having successfully defended her transdisciplinary research on “The Europeanisation of health systems: a small state perspective”. She is the author of several publications in public health and European health policy.
Between 2016 and 2020 she served as the President of the European Public Health Association (EUPHA) where she was actively involved in health advocacy at the European level.
In 2020, Dr Azzopardi-Muscat joined WHO/Europe and was appointed Director of the Division of Country Health Policies and Systems She served continuously in that position until her re-appointment as Director Health Systems in June 2025.
She is an associate professor at the University of Malta and a visiting scholar at the University of Maastricht.
In 2024 she was awarded the Andrija Stampar medal by the Association for Public Health Schools of the European Region (ASPHER) and in 2025 she was awarded an Honorary Fellowship by the Faculty of Public Health of the United Kingdom in recognition of her important contributions to public health.
Dr Azzopardi-Muscat is married to Dr Conrad Azzopardi and has three children Aidan, Sereena and Nathan.
Plenary Session: Pragmatic Trials—Bridging Research and Real-World Care
While explanatory clinical trials, which focus on evaluating therapeutic efficacy under ideal circumstances, are crucial for learning about new therapeutic interventions, they often include non-representative patients due to stringent eligibility criteria. Additionally, they often use intermediate endpoints, which can lead to uncertainty about the applicability of study results to patients in the real world. Therefore, they may not offer the best setup to address clinically meaningful daily clinical questions based on patient-relevant endpoints, highlighting the need for optimizing therapeutic strategies. This can be partly achieved by incorporating more pragmatic elements into cancer clinical trials conducted in real-life settings to enhance patient-centricity, efficiency, and the generalizability of evidence. This approach could also consider the interests and needs of stakeholders in healthcare, HTA agencies, clinicians, payers, and most importantly, patients and caregivers. However, these more pragmatic trials, especially those addressing the overutilization of therapeutic interventions, are not without their challenges. Patient acceptability, trial designs and feasibility, as well as fitness for regulatory frameworks and, finally, financial resources to conduct such trials, represent some of the most concerning challenges. The panel will attempt to disentangle the role, benefits, and challenges of pragmatic trials. How pragmatic trials could help re-engineer the process of development into access. Can pragmatic clinical trials be part of the solution to addressing disparities and inequalities in access to clinical trials, thereby bringing faster therapeutic progress to all?
Moderator
-
Denis Lacombe, MD
European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium
Denis Lacombe graduated with his MD from the University of Marseilles (France) in 1988 and obtained a Master Post-Doctoral Fellowship at The Roswell Park Cancer Institute (Buffalo, NY USA) for research in pharmacology and pharmacokinetics from 1989 to 1991. From 1991 to 1993, he worked as a Clinical Research Advisor in charge of the development of a new drug in oncology in the pharmaceutical industry.
Dr Lacombe joined the EORTC in 1993 as a research fellow and quickly became a very active and productive Clinical Research Physician involved in the conduct of clinical research from protocol development through publication for a number of oncology indications from phase I to phase III. Dr Lacombe contributed to the strategic evolution of the EORTC pan-European clinical and translational research infrastructure as well as developing partnerships with multiple stakeholders.
Dr Lacombe rose to the position of Director EORTC Headquarters in 2010, was appointed Director General in April 2015 and Chief Executive Officer in June 2021. In his current position, Denis Lacombe leads all activities promoting the EORTC as a major European organization in Cancer Clinical and Translational Research, including scientific activities, public relations and medium-term strategies as defined by the EORTC Board as well as internal and external communications.
Speakers
-
Antonella M Cardone, MBA
Cancer Patients Europe, Brussels, Belgium
Antonella Cardone is the CEO of Cancer Patients Europe, a pan-European all-cancer patient association. She is a Patient Advocacy Expert and Advisor to the Board of Pancreatic Cancer Europe (PCE), uniting physicians, patients, politicians, journalists, academia, and industry, and she is a member of Inspire2Live.
Antonella led the European Cancer Patient Coalition (ECPC) and served as Executive Director of the Fit for Work Global Alliance.
With 25 years of nonprofit experience in health, social, and employment sectors, she also directed the Global Smoke-free Partnership of the American Cancer Society.
Antonella holds Master's degrees in Science and Business Administration. She has been on the Boards of All.Can and Pancreatic Cancer Europe, where she was vice-chair.
-
Michael Zaiac, MD, PhD
Daiichi Sankyo Europe GmbH, Zürich, Switzerland
I am deeply passionate about science and people—a synergy that led me to pursue a career in medicine. Following the completion of my undergraduate studies in Berlin, I embarked on a surgical career in both the UK and Germany. Over time, I found my true calling in surgical oncology, where I specialized in caring for patients with breast cancer, sarcoma, melanoma, and other malignancies.
Motivated by a vision to bridge science with patient care and to broaden treatment options for cancer patients, I transitioned into industry research. Since then, I have successfully led teams of varying sizes across clinical research, development, commercial functions, and medical affairs. My contributions have supported the development and launch of therapies spanning oncology, immunology, cardiovascular disease, transplantation, and infectious diseases.
Throughout my career, I have attained a Research MD, an MBA, FRCS and FFPM qualifications, specialty registration, and the honorary GFMD. My work has been published across multiple disciplines, including surgery, medical affairs, public health, medicine development, and the application of artificial intelligence in healthcare.
-
Beate Wieseler
IQWiG, Köln, Germany
Dr. Beate Wieseler is Head of the Department of Drug Assessment at the German Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG), Germany’s Health Technology Assessment agency. At IQWiG she is responsible for the scientific assessment of pharmaceuticals, the development of assessment methods as well as in the Institute’s collaboration with German and international external parties. Currently, Beate Wieseler also is the Chair of the Methodological and Procedural Guidance Subgroup of the European HTA Coordination Group.
Prior to joining IQWiG in 2005, Beate Wieseler worked in clinical research and regulatory affairs for about 10 years. Beate Wieseler holds a Diploma in Biology from the University of Bonn and a Dr. rer. nat. from the University of Freiburg, Germany.
-
Richard Sullivan, MD, PhD
Institute of Cancer Policy, Centre for Conflict & Health Research, King's College London, London, United Kingdom
Richard Sullivan is Professor of Cancer & Global Health at King’s College London (KCL). He is the Director of both KCL’s Institute of Cancer Policy and the Centre for Conflict & Health Research. Richard is a senior NCD advisor to the World Health Organisation and leads the World Bank cancer program. Richard is a Fellow at the Centre for Global Development and a UK representative to the WHO IARC Scientific Council. He has a wide range of research programs from cancer systems strengthening, political economy of cancer, pharmaceutical policy, through to global cancer surgery. In conflict and health Richard’s teams work on health security intelligence, global health security, and health systems strengthening in conflict. Richard trained in surgical oncology (urology) with a PhD in Biochemistry from University College London. He was previously Clinical Director of Cancer Research UK and past Director of the Council for Emerging National Security Affairs.
-
Natasha Azzopardi-Muscat, MD, PhD
WHO Europe, Copenhagen, Denmark
Dr Natasha Azzopardi-Muscat, Director of the Division of Health Systems, WHO Regional Office for Europe.
Dr Natasha Azzopardi-Muscat is a medical doctor and a specialist in public health medicine.
Following her qualification as a medical doctor from the University of Malta in 1995, Dr Azzopardi-Muscat worked in various clinical specialties, including maternal and child health, mental health, and primary care. Having successfully completed a Master’s Degree in Health Services Management at the London School of Hygiene and Tropical Medicine and the London School of Economics and Political Science she returned to work at the Ministry of Health in Malta.
Between 2001 and 2013, she occupied various senior positions in the Ministry including Director for EU and International Affairs, Director General for Strategy and Chief Medical Officer.
In 2016 she obtained her PhD from the University of Maastricht having successfully defended her transdisciplinary research on “The Europeanisation of health systems: a small state perspective”. She is the author of several publications in public health and European health policy.
Between 2016 and 2020 she served as the President of the European Public Health Association (EUPHA) where she was actively involved in health advocacy at the European level.
In 2020, Dr Azzopardi-Muscat joined WHO/Europe and was appointed Director of the Division of Country Health Policies and Systems She served continuously in that position until her re-appointment as Director Health Systems in June 2025.
She is an associate professor at the University of Malta and a visiting scholar at the University of Maastricht.
In 2024 she was awarded the Andrija Stampar medal by the Association for Public Health Schools of the European Region (ASPHER) and in 2025 she was awarded an Honorary Fellowship by the Faculty of Public Health of the United Kingdom in recognition of her important contributions to public health.
Dr Azzopardi-Muscat is married to Dr Conrad Azzopardi and has three children Aidan, Sereena and Nathan.
-
Francesco Pignatti, MD
European Medicines Agency, Amsterdam, Netherlands
Francesco Pignatti graduated as Medical Doctor at the University of Rome. In 1995 he became Research Fellow at the EORTC Data Center in Brussels, Belgium. In 1997 he obtained a Master of Science degree in Biostatistics from the University of Limburg, Belgium. In 1999 he joined the European Medicines Agency (EMA), which is located in Amsterdam since 2019. From 2009 to 2023 he was appointed Head of the Office of Oncology and Haematology, he is currently Scientific Adviser for Oncology. His main regulatory science interests include cancer drug regulation, benefit-risk analysis, and stated preference studies.
Wed 12 Nov
11:30 - 12:45
Plenary Session: Special Remarks and Leadership Reports
As ISPOR Europe 2025 draws to a close, join us for final reflections from this year’s conference. ISPOR’s Chief Executive Officer will share key takeaways from the conference, and our Chief Science Officer will share important updates on ISPOR’s scientific direction and how members can engage.
Immediately following the opening presentations, the scientific plenary panel will take the stage.
Speakers
Plenary Session: RWE in European Healthcare Decision Making—What's in It for Patients?
Real-World Evidence (RWE) is increasingly shaping healthcare decision-making across Europe, not just for systems and stakeholders, but for the patients they serve. By capturing how treatments perform in everyday settings, RWE offers critical insights into patient outcomes, experiences, and unmet needs. At the heart of European efforts like DARWIN EU, collaborative networks are laying the groundwork for more connected, consistent, and patient-centered evidence generation. These initiatives aim to translate complex real-world data (RWD) into actionable knowledge that improves safety, access, and effectiveness of treatments across diverse patient populations. This plenary session will discuss the opportunities and challenges of RWE from a multi-stakeholder perspective and will explore how strategic cross-border partnerships and technological advancements—including AI—are helping to realize RWE’s full potential for patients. From regulators to researchers, all stakeholders have a role to play in ensuring that RWE efforts deliver meaningful, measurable value for patients.
Moderator
-
Karen Facey, BSc, PhD
University of Edinburgh, Utrecht, Netherlands
Karen Facey worked as a senior statistician in pharma and medicines regulation before moving to Scotland in 2000 to setup the first national HTA agency. Since 2003, she has been an independent consultant working with all stakeholders on matters related to HTA, real-world data and patient involvement. She has also served for 10 years on the governing board of regional and national health boards in Scotland and is a member of the national non-medicines appraisal committee. Karen is now an senior HTA advisor to the RWE4Decisions learning network and the Guidelines for RWE Generation and SUSTAIN-HTA projects via the Universities of Oxford and Utrecht. She is also a member of the Myeloma Patients Europe patient evidence research committee.
Speakers
-
Maria Dutarte
European Patients’ Academy on Therapeutic Innovation (EUPATI), Utrecht, Netherlands
Maria Dutarte is the Executive Director of the European Patients’ Academy on Therapeutic Innovation (EUPATI). Maria has previously worked for the European AIDS Treatment Group (EATG) coordinating patient involvement in a number of training initiatives and scientific projects. She has also worked for different scientific and international organisations, e.g. French National Research Center for Scientific Research (CNRS), International AIDS Society (IAS), The Global Fund to Fight AIDS, Tuberculosis and Malaria and The International Foundation for Science (IFS). Her educational background is in International Education and Communications.
-
Pall Jonsson, BSc, PhD
National Institute for Health and Care Excellence (NICE), Manchester, United Kingdom
Páll Jónsson is Programme Director for Data and Evidence at UK’s National Institute for Health and Care Excellence (NICE). He has a strategic role in ensuring NICE is at the forefront of harnessing new and emerging opportunities to inform NICE’s guidance for the health and care sectors. His remit includes data access and analysis, real-world evidence methods, implementation of AI in HTA and guidelines, and evidence services.
Páll holds a doctorate in biochemistry and bioinformatics from the University College London. Prior to his current role, he served as Associate Director for Science Policy and Research, overseeing a portfolio of international research projects in areas such as big data and real-world evidence.
-
Sofie Gustafsson, PhD
Pfizer, Stockholm, Sweden
Dr. Sofie Gustafsson is the Global Director of RWE Partnerships and Innovation for International Developed Markets at Pfizer, leading strategic data collaborations for real-world evidence studies across all therapeutic areas. She is an affiliated researcher at the Karolinska Institute, a licensed pharmacist, and holds a PhD in economics. Internationally, Dr. Gustafsson has contributed to initiatives such as the International Horizon Scanning Initiative (IHSI), several IMI/IHI consortiums, and Nordic collaborations such as the Nordic Pharmaceutical Forum. Previously, at Sweden’s HTA agency TLV, she led several governmental assignments on the data access and methodologies for use in HTA decision-making and developed value-based pricing frameworks for therapies targeting rare diseases.
-
Renske Los, PhD
Erasmus MC, Rotterdam, Netherlands
Dr. Renske Los is Assistant Professor of Medical Informatics at Erasmus MC, Rotterdam. Her work focuses on harmonising health data to support real-world evidence and outcomes research. As co-lead of OHDSI Netherlands and OHDSI Europe, she promotes adoption of the OMOP Common Data Model to improve data comparability and reusability across institutions and borders. She is actively involved in European hospital benchmarking and standardising Patient Reported Outcomes data. With a background in EHR implementation and teaching Evidence-Based Medicine, Renske is committed to enhancing the quality and usability of clinical data for research and policy.
